Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ Jr, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Morgan RJ Jr, et al. Among authors: hamasaki v. Cancer Res. 1998 Jul 1;58(13):2793-800. Cancer Res. 1998. PMID: 9661893 Clinical Trial.
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
Morgan RJ Jr, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, Leong L, Margolin K, Niland J, Raschko J, Somlo G, Carroll M, Chow W, Tetef M, Hamasaki V, Yen Y, Doroshow JH. Morgan RJ Jr, et al. Among authors: hamasaki v. Cancer Chemother Pharmacol. 2003 Jun;51(6):459-64. doi: 10.1007/s00280-003-0605-0. Epub 2003 Apr 15. Cancer Chemother Pharmacol. 2003. PMID: 12695856 Clinical Trial.
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Newman EM, Carroll M, Akman SA, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata S, Somlo G, Tetef M, Yen Y, Ahn CW, Doroshow JH. Newman EM, et al. Among authors: hamasaki v. Cancer Chemother Pharmacol. 1997;39(3):254-8. doi: 10.1007/s002800050569. Cancer Chemother Pharmacol. 1997. PMID: 8996529 Clinical Trial.
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ Jr, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J. Morgan RJ Jr, et al. Among authors: hamasaki v. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2337-45. Clin Cancer Res. 1997. PMID: 9815632 Clinical Trial.
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Raschko JW, Synold TW, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Shibata SI, Somlo G, Tetef ML, Yen Y, ter Veer A, Doroshow JH. Raschko JW, et al. Among authors: hamasaki v. Cancer Chemother Pharmacol. 2000;46(5):403-10. doi: 10.1007/s002800000142. Cancer Chemother Pharmacol. 2000. PMID: 11127945 Clinical Trial.
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Morgan RJ, et al. Among authors: hamasaki v. Bone Marrow Transplant. 2001 Nov;28(9):859-63. doi: 10.1038/sj.bmt.1703243. Bone Marrow Transplant. 2001. PMID: 11781646 Clinical Trial.
Fluorouracil and leucovorin in advanced breast cancer.
Doroshow JH, Margolin K, Leong L, Akman S, Morgan R Jr, Raschko J, Somlo G, Hamasaki V, Womack E, Newman E, et al. Doroshow JH, et al. Among authors: hamasaki v. Adv Exp Med Biol. 1993;339:187-93; discussion 195. doi: 10.1007/978-1-4615-2488-5_19. Adv Exp Med Biol. 1993. PMID: 8178716 Review. No abstract available.
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Raschko J, Shibata S, Tetef M, Molina A, Berenson RJ, Forman SJ, Doroshow JH. Somlo G, et al. Among authors: hamasaki v. Blood. 1997 Mar 1;89(5):1521-8. Blood. 1997. PMID: 9057632 Free article.
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V, Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Simpson J, Molina A. Somlo G, et al. Among authors: hamasaki v. J Clin Oncol. 1997 Aug;15(8):2882-93. doi: 10.1200/JCO.1997.15.8.2882. J Clin Oncol. 1997. PMID: 9256132
16 results